Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer.

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer. J Clin Oncol. 2021 03 01; 39(7):723-733.

View in: PubMed

subject areas

Adult
Aged
Aged, 80 and over
Carcinoma, Non-Small-Cell Lung
Clinical Trials, Phase III as Topic
Disease Progression
Female
Humans
Immunotherapy
Lung Neoplasms
Male
Middle Aged
Randomized Controlled Trials as Topic
Time Factors
Tubulin Modulators
Young Adult

authors with profiles

Everett E. Vokes
Marina Chiara Garassino